Can engineered immune cells calm autoimmune blood disorders?
Disease control
Not yet recruiting
This phase 1 trial tests a one-time infusion of AZD0120, a CAR-T cell therapy that targets CD19 and BCMA, in people with relapsed or refractory immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA). Participants receive a short course of bendamustine before th…
Phase 1 • Sponsor: Saurabh Dahiya • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC